Puerarin rescues intestinal barrier dysfunction and ameliorates colitis via NRF2-associated inhibition of ferroptosis

Objective The study aimed to clarify the link between ferroptosis and intestinal barrier dysfunction, investigate the underlying mechanisms of puerarin in colitis, and clarify the involvement of NRF2 signaling and gut microbiota modulation in its protective effects. Materials and methods Colitis was induced by dextran sulfate sodium (DSS) to evaluate the protective effects of puerarin. We combined RNA-seq with an analysis of public Gene Expression Omnibus (GEO) datasets to identify potential ferroptosis-related therapeutic targets in ulcerative colitis. Ferroptosis-related markers were assessed. Pharmacological interventions and small interfering RNA (siRNA)-mediated gene silencing were combined to investigate the potential mechanisms underlying the protective effects of puerarin against ferroptosis and on intestinal barrier integrity. Finally, 16S rRNA sequencing was conducted to characterize the gut microbiota and explore its potential association with puerarin treatment. Results Puerarin significantly ameliorated colitis, as evidenced by a reduced disease activity index, increased colon length, and reduced histological injury. RNA-seq suggested that ferroptosis was a potential mechanism underlying the protective effects of puerarin. Subsequent experiments indicated that DSS- or LPS-induced injury activated ferroptosis. Moreover, erastin-induced ferroptosis impaired intestinal barrier integrity, and ferrostatin-1 (Fer-1) reversed this impairment, supporting a contribution of ferroptosis to intestinal barrier disruption. Puerarin improved intestinal barrier integrity, at least partly by suppressing ferroptosis, and this effect was accompanied by increased NFE2L2 mRNA and NRF2 protein levels. Both ML385 treatment and NFE2L2 knockdown largely abolished the protective effects of puerarin, supporting the conclusion that these effects are at least partly mediated through NRF2 signaling. 16S rRNA sequencing revealed that puerarin partially modulated gut microbiota composition in DSS-induced colitis mice. Conclusion Puerarin ameliorates experimental colitis by protecting intestinal barrier function, at least partly through NRF2-associated inhibition of ferroptosis.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-16
DOI
https://doi.org/10.3389/fmed.2026.1996156
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Puerarin rescues intestinal barrier dysfunction and ameliorates colitis via NRF2-associated inhibition of ferroptosis

XU Daogu, Zhanyi Zhou, Zhe Chen, Shaopeng Sun et al.
Frontiers in Medicine
Inflammatory Bowel Disease
article

Puerarin rescues intestinal barrier dysfunction and ameliorates colitis via NRF2-associated inhibition of ferroptosis

XU Daogu, Zhanyi Zhou, Zhe Chen, Shaopeng Sun, Chuyu Wang, Yijie Lou, Hao Fang, Shuwen Wu
article en

Abstract

Objective The study aimed to clarify the link between ferroptosis and intestinal barrier dysfunction, investigate the underlying mechanisms of puerarin in colitis, and clarify the involvement of NRF2 signaling and gut microbiota modulation in its protective effects. Materials and methods Colitis was induced by dextran sulfate sodium (DSS) to evaluate the protective effects of puerarin. We combined RNA-seq with an analysis of public Gene Expression Omnibus (GEO) datasets to identify potential ferroptosis-related therapeutic targets in ulcerative colitis. Ferroptosis-related markers were assessed. Pharmacological interventions and small interfering RNA (siRNA)-mediated gene silencing were combined to investigate the potential mechanisms underlying the protective effects of puerarin against ferroptosis and on intestinal barrier integrity. Finally, 16S rRNA sequencing was conducted to characterize the gut microbiota and explore its potential association with puerarin treatment. Results Puerarin significantly ameliorated colitis, as evidenced by a reduced disease activity index, increased colon length, and reduced histological injury. RNA-seq suggested that ferroptosis was a potential mechanism underlying the protective effects of puerarin. Subsequent experiments indicated that DSS- or LPS-induced injury activated ferroptosis. Moreover, erastin-induced ferroptosis impaired intestinal barrier integrity, and ferrostatin-1 (Fer-1) reversed this impairment, supporting a contribution of ferroptosis to intestinal barrier disruption. Puerarin improved intestinal barrier integrity, at least partly by suppressing ferroptosis, and this effect was accompanied by increased NFE2L2 mRNA and NRF2 protein levels. Both ML385 treatment and NFE2L2 knockdown largely abolished the protective effects of puerarin, supporting the conclusion that these effects are at least partly mediated through NRF2 signaling. 16S rRNA sequencing revealed that puerarin partially modulated gut microbiota composition in DSS-induced colitis mice. Conclusion Puerarin ameliorates experimental colitis by protecting intestinal barrier function, at least partly through NRF2-associated inhibition of ferroptosis.

Frontiers in MedicineVol. 13
Zhejiang Chinese Medical University (CN), Wenzhou Hospital of Traditional Chinese Medicine (CN), Zhejiang Provincial Hospital of TCM (CN), The First People's Hospital of Xiaoshan District, Hangzhou (CN)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon